ABY-071

ABY-071 is a radioligand therapy candidate aimed at tumor cells that express B7-H3, regardless of their position in the body.

B7-H3 is a cell surface immunomodulatory glycoprotein overexpressed by many different types of cancers, whereas its expression is low in most normal organs and tissues. This makes it a promising target for cancer therapies. B7-H3 inhibits tumor specific immune responses and promotes tumor cell proliferation and invasion. High B7-H3 expression is generally associated with poor prognosis.

ABY-071 with the radioisotope lutetium-177 emits cytotoxic beta radiation, exerting irreversible damage to cancer cells upon binding. ABY‑071, has demonstrated favorable biodistribution, strong tumor‑to‑organ ratios, and compelling antitumor efficacy in preclinical models. A candidate drug was selected in 2025. ABY-071 is currently advancing through IND-enabling development.